Modified Pfizer/BioNTech vaccination against Covid mutation called Omicron could be available soon enough. In the words of CEO of BioNTech, Ugur Şahin, „We can deliver in a very timely manner.” This event is favourable in both financial and technological ways.
On the other hand, Moderna - one of the biggest competitors - is suing both partner firms. Covid vaccination developers had been accused of patent infringement. Companies reportedly copied mRNA technology, which Moderna developed. The lawsuit was filed in US and Germany. However, Pfizer would “vigorously defend” itself against all the allegations. It is hard to judge the situation this soon or predict damage, this might cause. It is worth bearing in mind, this situation has only one winner.
“With our strong performance year to date, we believe to be well on track to achieve our previous financial guidance for the ongoing financial year,” said Jens Holstein, CFO of BioNTech.  In the chart below you can see Key Q2 Financial Results of BioNTech.
Top sixth European technological company - according to BCMcomparison - has stock price, despite macroeconomics insecurities. BNTX price in the chart below is fluctuating in the past six months and recent lawsuit will may have the biggest influence in determination of the future price movements. * 
In spite of all that, BioNTech is long-termly, naturally growing company with great EPS ratio ($6.87) in the second quarter of 2022 and, has signed and agreement with U.S. government to provide vaccine doses, commenced construction of vaccine manufacturing facility in Africa etc. In other words, BioNTech is not going to disappear.
Biopharmaceutical New Technologies is a German company known for research and development of vaccines and medicaments based on mRNA. BioNTech has developed the Covid-19 mRNA based vaccination partnering with Pfizer in 2020. Since then, seemingly endless fight against Covid-19 and its mutations, became number one interest of the company.
* Past performance is no guarantee of future results.
[1,2] Forward-looking statements are based on assumptions and current expectations, which may be inaccurate, or based on the current economic environment which is subject to change. Such statements are not guaranteeing of future performance. They involve risks and other uncertainties which are difficult to predict. Results could differ materially from those expressed or implied in any forward-looking statements.
The content of this material constitutes marketing communication and should not be considered as any type of investment advice and/or investment research and/or a solicitation for any transactions. This material was prepared for informational/educational purposes only and does not imply an obligation to perform investment transactions nor does it guarantee or predict future performance. BCM Begin Capital Markets Cy Ltd and its relevant persons including affiliates, agents, directors, or employees do not guarantee the accuracy, validity, timeliness, or completeness of any information/data provided by third parties and assume no liability for any loss arising from any investment made based on the said information/data. Past performance is no guarantee of future results.